Incepta says has capacity to produce 1.2bn vaccines a year | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Saturday
July 12, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SATURDAY, JULY 12, 2025
Incepta says has capacity to produce 1.2bn vaccines a year

Health

TBS Report
18 March, 2021, 08:10 pm
Last modified: 19 March, 2021, 01:50 pm

Related News

  • US Health Secretary Kennedy guts vaccine advisory committee
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj
  • Umrah pilgrims struggle with abrupt meningitis vaccination requirement amid shortage
  • Vaccination, early screening can prevent cervical cancer death for women
  • Study on Bangladeshi children confirms lasting impact of typhoid vaccine

Incepta says has capacity to produce 1.2bn vaccines a year

‘We are the only pharmaceutical company in the country that manufactures vaccines using state-of-the-art technology in compliance with safety protocols’

TBS Report
18 March, 2021, 08:10 pm
Last modified: 19 March, 2021, 01:50 pm
Incepta says has capacity to produce 1.2bn vaccines a year

Incepta Pharmaceuticals authorities say it has the capacity to produce 1.2 billion single doses of bacterial and viral vaccines.

If approved, the company will be able to make Covid-19 vaccine in the country, said the company.

Health Minister Zahid Maleque visited the Incepta vaccine plant on Thursday and the company's Chairman and Managing Director Abdul Muktadir gave journalists a presentation on how to make a vaccine.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Muktadir said they had four German technology filling lines and it is possible for them to produce 400 million single doses of vaccines per line every year.

"So, it is possible to make 1.2 billion doses of vaccines here every year, even if it is Covid-19 vaccine, since we also have a cold chain to store 500 million doses of vaccines," he maintained.

Muktadir claimed that they are the only pharmaceutical company in Bangladesh that manufactures vaccines using state-of-the-art technology in compliance with safety protocols.

"Now if we get a bulk of corona vaccines, we will be able to go into production in two weeks, however, once the master seed is obtained, it can take about 12 weeks to go into production," he said.

In this case, the government cooperation is needed because if the government does not want, it is not possible to bring the vaccine in the country alone, said the Incepta managing director.

While inspecting the factory, Health Minister Zahid Maleque said the government would provide all kinds of assistance to the private sector if the country could produce world-class vaccines as per the Good Manufacturing Practice.

In this case, not only Incepta, the government is willing to help any private organisation, he added.

Incepta has already earned the trust of all by creating multiple life-saving vaccines, the minister noted, saying any opportunity to produce coronavirus vaccine in Bangladesh will actually put the drug company ahead in terms of preparation.

The prime minister herself is sincere about the production of corona vaccine in the country, Zahid said, adding, "We are buying 30 million vaccines from Serum, but it will not meet our needs.

"In this case, the premier has asked me to check the capability of private firms."

The government will buy the vaccine if any local firm can provide it according to the policy of the World Health Organisation, said the minister.

"If Incepta can provide us with a quality vaccine, we will consider it. We have some limitations, but we are working on them," he added.

Meanwhile, Major General Mahbubur Rahman, director general of the Department of Drug Administration, said, "We have already written to the World Health

Organization and Oxford- AstraZeneca for vaccine bulk or master seed for vaccine production in the country.

"I hope they will tell us something positive. We are also in discussion with others."

Incepta says the company's vaccine production capability is not being fully utilised now. About half its capacity (628 million) is being used.

Incepta is the first life-saving international standard vaccine manufacturer in Bangladesh. Its vaccine factory in Savar officially started its journey in June 2011.

The company is producing and marketing more than 10 vaccines including rabies, rabies-IG, hepatitis B, typhoid, tetanus, tetanus-IG, measles-rubella, antivenom, flu and meningitis.

Incepta has been making these vaccines for the country as well as exporting them to 12 countries of the world.
 

Bangladesh / Top News

Incepta / Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Bangladesh and US hold tariff talks on 11 July 2025. Photo: CA Press Wing
    Dhaka, Washington to continue inter-ministerial dialogue as tariff talks end without full consensus
  • Infograph: TBS
    Costly delays and doubts: Dhaka's BRT project spirals further with 55% cost jump
  • Representational image
    In addition to 35% tariff, US demands 40% local value addition for 'Made in Bangladesh' goods

MOST VIEWED

  • In terms of stream of education, girls maintained their excellence as well. Photo: TBS
    SSC 2025: Girls dominate boys by over 5%
  • Photo: Mohammad Minhaj Uddin/TBS
    SSC, equivalent results: Pass rate drops to 68.45%, GPA-5 also declines
  • The overall pass rate across all boards this year, 68.45%, is significantly lower than last year's. Photo: Focus Bangla
    SSC 2025: Rajshahi board records highest pass rate, Barishal lowest
  • How S Alam’s Global Islami Bank cooked Tk2,259cr loss into Tk128cr profit
    How S Alam’s Global Islami Bank cooked Tk2,259cr loss into Tk128cr profit
  • Representational image. Photo: TBS
    SSC 2025: 73.63% pass rate among technical students, 68.09% at Madrasahs
  • Economist Abul Barkat; Photo: Courtesy
    Economist Abul Barkat arrested in graft case

Related News

  • US Health Secretary Kennedy guts vaccine advisory committee
  • Govt plans to relocate country's first vaccine plant from Gopalganj to Munshiganj
  • Umrah pilgrims struggle with abrupt meningitis vaccination requirement amid shortage
  • Vaccination, early screening can prevent cervical cancer death for women
  • Study on Bangladeshi children confirms lasting impact of typhoid vaccine

Features

After India's visa restriction, China's Kunming is drawing Bangladeshi patients

After India's visa restriction, China's Kunming is drawing Bangladeshi patients

14h | Panorama
Photo: Collected/BBC

What Hitler’s tariff policy misfire can teach the modern world

1d | The Big Picture
Illustration: TBS

Behind closed doors: Why women in Bangladesh stay in abusive marriages

1d | Panorama
Purbachl’s 144-acre Sal forest is an essential part of the area’s biodiversity. Within it, 128 species of plants and 74 species of animals — many of them endangered — have been identified. Photo: Syed Zakir Hossain/TBS

A forest saved: Inside the restoration of Purbachal's last Sal grove

1d | Panorama

More Videos from TBS

Renowned economist Abul Barkat imprisoned

Renowned economist Abul Barkat imprisoned

12h | TBS Today
All of Iran's uranium still intact, Israel claims

All of Iran's uranium still intact, Israel claims

12h | TBS World
Trump-Netanyahu in new strategy on Gaza issue

Trump-Netanyahu in new strategy on Gaza issue

14h | TBS World
Shocking science: why birds stay safe on electricity lines

Shocking science: why birds stay safe on electricity lines

14h | TBS Stories
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net